Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) [Yahoo! Finance]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance
Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity. 10 stocks we like better than Avidity Biosciences › Shares in Avidity Biosciences (NASDAQ: RNA) soared by 42% in the week to Friday morning following the announcement of a unanimous deal for Avidity to be acquired by Novartis (NYSE: NVS) for $72 per share. The deal values Avidity at $12 billion. However, that's not all Avidity shareholders will receive. A complicated deal Novartis is acquiring Avidity to enhance its developmental pipeline by leveraging Avidity's expertise in a class of ribonucleic acid (RNA) therapeutics known as antibody oligonucleotide conjugates (AOC). A new class of therapeutics, AOCs offer the potential for targeted precision delivery of gene-modulating oligonucleotides that regulate genes for treatment purposes. As such, Novartis will acquire Avidity's pipeline of treatments for muscular dystrophy, which are currently in clinical trials However,
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals [Yahoo! Finance]Yahoo! Finance
- SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody [Yahoo! Finance]Yahoo! Finance
- Avidity Biosciences (NASDAQ:RNA) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.MarketBeat
- Avidity Biosciences (NASDAQ:RNA) was given a new $72.00 price target on by analysts at Evercore ISI.MarketBeat
- Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge [Yahoo! Finance]Yahoo! Finance
RNA
Earnings
- 11/10/25 - Miss
RNA
Sec Filings
- 1/14/26 - Form DFAN14A
- 1/12/26 - Form DFAN14A
- 1/12/26 - Form DEFA14A
- RNA's page on the SEC website